GlassScriptPhysician profile
Lisa M Rossi
NPI 1275653933
$39,842.82
in general payments reported to CMS, 2019-2025
36 companies · $11K in 2025
The $11K reported for 2025 was more than what 93% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,548 · 2020: $349 · 2021: $798 · 2022: $1,864 · 2023: $2,198 · 2024: $17K · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20K · Food and Beverage: $7,947 · Travel and Lodging: $1,816 · Education: $310.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20,210.00 |
| Food and Beverage | $7,947.30 |
| Travel and Lodging | $1,816.21 |
| Education | $309.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $23,097.63 | 2024-2025 | Voquezna |
| Allergan, INC. | $5,998.00 | 2019-2020 | |
| Abbvie INC. | $2,618.12 | 2019-2025 | Rinvoq, Linzess, Skyrizi |
| Janssen Biotech, INC. | $1,932.42 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $1,041.05 | 2019-2025 | Entyvio, Eohilia |
| Celgene Corporation | $562.31 | 2021-2024 | Zeposia |
| Ardelyx, INC. | $497.41 | 2022-2025 | Ibsrela |
| E.R. Squibb & Sons, L.L.C. | $420.57 | 2021-2023 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $397.42 | 2019-2024 | Trulance, Xifaxan |
| Regeneron Healthcare Solutions, INC. | $371.23 | 2022-2025 | Dupixent |
| Lilly USA, LLC | $325.12 | 2024-2025 | Omvoh |
| Pfizer INC. | $249.43 | 2019-2025 | |
| Ferring Pharmaceuticals INC. | $203.65 | 2019-2024 | Rebyota, Clenpiq |
| Genzyme Corporation | $199.63 | 2020-2025 | |
| Gilead Sciences, INC. | $189.26 | 2024-2025 | Livdelzi |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $182.68 | 2024-2025 | Sucraid, Sucraid |
| Ironwood Pharmaceuticals, INC | $170.11 | 2020-2024 | Linzess |
| Boehringer Ingelheim Pharmaceuticals, INC. | $168.81 | 2023-2024 | Cyltezo |
| Madrigal Pharmaceuticals | $168.47 | 2025 | Rezdiffra |
| Boston Scientific Corporation | $145.51 | 2024 | Exalt Model D |
| Fresenius Kabi USA, LLC | $138.73 | 2023-2024 | Idacio |
| Celltrion USA INC. | $116.18 | 2023-2024 | Zymfentra, Yuflyma |
| Nestle Healthcare Nutrition INC. | $114.82 | 2021-2023 | |
| Intercept Pharmaceuticals, INC. | $103.30 | 2021-2023 | Ocaliva |
| Aimmune Therapeutics, INC. | $99.18 | 2025 | Zenpep |
| Exact Sciences Corporation | $51.22 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $49.96 | 2019-2020 | |
| Erbe USA INC | $40.18 | 2024-2025 | Vio#/Apc3/Erbejet2 |
| Braintree Laboratories, INC. | $36.27 | 2024-2025 | Suflave, Sutab |
| Ipsen Biopharmaceuticals, INC | $33.65 | 2024 | Bylvay |
| Alfasigma USA, INC. | $32.59 | 2020 | |
| Organon LLC | $31.16 | 2022-2023 | Renflexis |
| Sandoz INC. | $21.77 | 2023 | Hyrimoz |
| Shionogi INC | $13.76 | 2020 | |
| Redhill Biopharma INC. | $11.98 | 2022 | |
| Janssen Pharmaceuticals, INC | $9.24 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Rossi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.